Evaluation of quality of life indicators in NSTEMI patients depending on plasma level st2, nature of coronary arteries lesion and other clinical characteristics

Abstract

The prevalence of myocardial infarction and the risk of adverse and fatal events in the early period lead to the search for a variety of non-invasive biomarkers, which have the ability to predict the course of the disease. One of the factors that has been actively studied recently is the growth stimulating factor expressed by the 2 (ST2) gene [1]. ST2 is a member of the family of interleukin-1 (IL-1) receptors with isoforms associated with membrane ST2 (ST2L) and soluble (sST2) forms. IL-33/ST2L signaling protects the myocardium from hypertrophy and fibrosis of the heart after pressure overload [2, 3]. Soluble ST2 acts as a bait receptor for IL-33 and prevents IL-33/ST2L interactions and subsequent cardioprotective cascade events. The aim of the study – to evaluate quality of life in NSTEMI patients based on plasma ST2 levels, the nature of coronary artery disease, and other clinical characteristics.